1-Aminomethyl-5-methoxyindane
Encyclopedia
1-Aminomethyl-5-methoxyindane (AMMI), is a drug
developed by a team led by David E. Nichols
at Purdue University
, which acts as a selective
serotonin releasing agent
(SSRA) and binds to the serotonin transporter
with similar affinity to DFMDA
.
Drug
A drug, broadly speaking, is any substance that, when absorbed into the body of a living organism, alters normal bodily function. There is no single, precise definition, as there are different meanings in drug control law, government regulations, medicine, and colloquial usage.In pharmacology, a...
developed by a team led by David E. Nichols
David E. Nichols
David E. Nichols is an American pharmacologist and medicinal chemist.Presently the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969...
at Purdue University
Purdue University
Purdue University, located in West Lafayette, Indiana, U.S., is the flagship university of the six-campus Purdue University system. Purdue was founded on May 6, 1869, as a land-grant university when the Indiana General Assembly, taking advantage of the Morrill Act, accepted a donation of land and...
, which acts as a selective
Binding selectivity
Binding selectivity refers to the differing affinities with which different ligands bind to a substrate forming a complex. A selectivity coefficient is the equilibrium constant for the reaction of displacement by one ligand of another ligand in a complex with the substrate...
serotonin releasing agent
Selective serotonin releasing agent
A selective serotonin releasing agent is a type of drug which selectively induces the release of serotonin from the pre-synaptic neuron into the synapse...
(SSRA) and binds to the serotonin transporter
Serotonin transporter
The serotonin transporter is a monoamine transporter protein.This protein is an integral membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons. This transport of serotonin by the SERT protein terminates the action of serotonin and recycles it...
with similar affinity to DFMDA
Difluoromethylenedioxyamphetamine
Difluoromethylenedioxyamphetamine is a substituted derivative of methylenedioxyamphetamine , which was developed by Daniel Trachsel and coworkers, along with the corresponding fluorinated derivatives of MDMA, MDEA, BDB and MBDB, with the aim of finding a non-neurotoxic drug able to be used as a...
.
See also
- 2CB-Ind2CB-Ind2CB-Ind is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B, discovered in 2006 by a team at Purdue University...
- 5-IAI5-Iodo-2-aminoindane5-Iodo-2-aminoindane is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. It was developed in the 1990s by a team led by David E. Nichols at Purdue University. 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans...
- JimscalineJimscalineJimscaline is a conformationally-restricted derivative of the cactus-derived hallucinogen mescaline, which was discovered in 2006 by a team at Purdue University led by David E. Nichols...
- MDAI5,6-Methylenedioxy-2-aminoindane5,6-Methylenedioxy-2-aminoindane is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent in vitro and produces entactogen effects in humans.- Chemistry :The chemical structure of MDAI is...
- MMAI5-Methoxy-6-methyl-2-aminoindane5-Methoxy-6-methyl-2-aminoindane , is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent and produces entactogen effects in humans...
- PMA